High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study.
High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study.
复制标题
高剂量静脉注射维生素 C 用于预防中度 COVID-19 肺炎病情加重。
DOI：
10.3389/fphar.2021.638556
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
Qu J
中科院分区：
文献类型：
--
作者：
Zhao B;Liu M;Liu P;Peng Y;Huang J;Li M;Wang Y;Xu L;Sun S;Qi X;Ling Y;Li J;Zhang W;Mao E;Qu J
背景资料：2019冠状病毒病（COVID-19）大流行继续影响全球多个国家，有效的治疗方案仍在开发中。在这项研究中，我们研究了大剂量静脉注射维生素C（HDIVC）预防中度COVID-19疾病加重的潜力。研究方法：在这项回顾性前后病例匹配的临床研究中，我们比较了接受HDIVC方案治疗的中度COVID-19患者的结局和临床病程（静脉注射维生素C，100 mg/kg/天，1 g/h，从入院起持续7天），为期1个月（2020年3月18日至4月18日，HDIVC组）与前两个月（2020年1月18日至3月18日）未接受HDIVC方案治疗的对照组。两组患者按年龄和性别1：1配对。结果：HDIVC组和对照组各55例。对于主要结局，两组之间从中度发展为重度的患者数量存在显著差异（HDIVC：4/55 vs.对照组：12/55，相对风险[RR] = 0.28 [0.08，0.93]，P = 0.03）。与对照组相比，第1周全身炎症反应综合征（SIRS）持续时间较短（P = 0.0004），第7天（入院后6-7天）SIRS发生率较低（2/21 vs 10/22，P = 0.0086）。此外，HDIVC组从第0天（入院时）到第7天（P = 0.04）的C反应蛋白水平较低（P = 0.005）和CD 4 + T细胞数量较高。与对照组相比，HDIVC组第7天的凝血指标水平（包括活化部分凝血活酶时间和D-二聚体）也有所改善。结论：HDIVC可能有利于限制COVID-19肺炎早期的病情加重，这可能与其改善炎症反应、免疫功能和凝血功能有关。需要进一步的随机对照试验来增强这些发现。
Background: Coronavirus disease 2019 (COVID-19) pandemic is continuing to impact multiple countries worldwide and effective treatment options are still being developed. In this study, we investigate the potential of high-dose intravenous vitamin C (HDIVC) in the prevention of moderate COVID-19 disease aggravation. Methods: In this retrospective before-after case-matched clinical study, we compare the outcome and clinical courses of patients with moderate COVID-19 patients who were treated with an HDIVC protocol (intravenous injection of vitamin C, 100 mg/kg/day, 1 g/h, for 7 days from admission) during a one-month period (between March 18 and april 18, 2020, HDIVC group) with a control group treated without the HDIVC protocol during the preceding two months (January 18 to March 18, 2020). Patients in the two groups were matched in a 1:1 ratio according to age and gender. Results: The HDIVC and control groups each comprised 55 patients. For the primary outcomes, there was a significant difference in the number of patients that evolved from moderate to severe type between the two groups (HDIVC: 4/55 vs. control: 12/55, relative risk [RR] = 0.28 [0.08, 0.93], P = 0.03). Compared to the control group, there was a shorter duration of systemic inflammatory response syndrome (SIRS) (P = 0.0004) during the first week and lower SIRS occurrence (2/21 vs 10/22, P = 0.0086) on Day 7 (6–7 days after admission). In addition, HDIVC group had lower C-reactive protein levels (P = 0.005) and higher number of CD4+ T cells from Day 0 (on admission) to Day 7 (P = 0.04).” The levels of coagulation indicators, including activated partial thromboplastin time and D-dimer were also improved in the HDIVC compared to the control group on Day 7. Conclusion: HDIVC may be beneficial in limiting disease aggravation in the early stage of COVID-19 pneumonia, which may be related to its improvements on the inflammatory response, immune function and coagulation function. Further randomized controlled trials are required to augment these findings.
登录
查看更多内容
影响因子：
3.9
作者：
Hemilä H;Chalker E
通讯作者：
Chalker E
维生素C的悠久历史：从预防普通感冒到治疗Covid-19的潜在帮助。
影响因子：
7.3
作者：
Cerullo G;Negro M;Parimbelli M;Pecoraro M;Perna S;Liguori G;Rondanelli M;Cena H;D'Antona G
通讯作者：
D'Antona G
影响因子：
158.5
作者：
Kaukonen, Kirsi-Maija;Bailey, Michael;Bellomo, Rinaldo
通讯作者：
Bellomo, Rinaldo
影响因子：
120.7
作者：
Fowler, Alpha A., III;Truwit, Jonathon D.;Halquist, Matthew
通讯作者：
Halquist, Matthew
影响因子：
39
作者：
Wu, Chaomin;Chen, Xiaoyan;Song, Yuanlin
通讯作者：
Song, Yuanlin